The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS|[sol]|BRAF wild-type colorectal cancer patients receiving irinotecan|[sol]|cetuximab

摘要

Background:The data from randomised trials suggested that primary tumour sidedness could represent a prognostic and predictive factor in colorectal cancer (CRC) patients, particularly during treatment with anti-epidermal growth factor receptor (EGFR) therapy. However, an in-deep molecular selection might overcome the predictive role of primary tumour location in this setting.